Larynx Cancer Clinical Trial
Official title:
A Phase I Trial of WEE1 Inhibition With Chemotherapy and Radiotherapy as Adjuvant Treatment, and a Window of Opportunity Trial With Cisplatin in Patients With Head and Neck Cancer
This trial is to determine what dose of a drug called AZD1775 can safely be given in combination with cisplatin before surgery and with chemo-radiotherapy after surgery in patients with Head and Neck Cancer. The Investigators will also get some preliminary information regarding the effectiveness of this combined treatment.
Patients with head and neck cancer with high-risk features are at increased risk of relapse after surgery. Surgery, often followed by cisplatin chemotherapy and radiotherapy is currently the standard treatment offered. Whilst chemo-radiotherapy improves cure rates, outcomes remain poor, and treatment has a significant impact on quality of life. Chemotherapy has yet to find a definitive role prior to surgery. There is therefore an urgent need to develop more effective treatments which improve cure rates for this patient population. The purpose of this trial is to see whether incorporating a drug called AZD1775 into the management of head and neck cancer offers the possibility of addressing these clinical issues. AZD1775 is a drug that has been shown to increase the effect of cisplatin and of radiotherapy when tested in the laboratory. The blood samples and tumour biopsies taken during the trial will be important in learning as much as possible about the effects of AZD1775 on the body and to investigate how the tumour might develop resistance to the drug. The WISTERIA trial is for patients aged between 18 and 70 years with cancer of the oral cavity, larynx and hypopharynx who are to undergo surgery. Patients recruited to Group A must have accessible tumours for re-biopsy, whilst patients recruited to Group B will be at high risk of relapse after surgery. The primary objective of this trial is to see what dose of AZD1775 can safely be given in combination with cisplatin before surgery (Group A) and with chemo-radiotherapy after surgery (Group B). The Investigators will also get some preliminary information regarding the effectiveness of this combined treatment. To find the safe and effective dose of AZD1775, different doses will be tested for each Group. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
| Completed |
NCT03292341 -
Evaluation of a Web-based Decision Aid Tool for Larynx Cancer (T3/T4) Patients.
|
N/A | |
| Completed |
NCT03653039 -
Comparison Between a Standard Tube and the Ultra-thin Tritube for Intubation of the Trachea and for Maintaining Access to the Trachea After Anaesthesia, in Patients With an Expected Difficult Direct Laryngoscopy
|
N/A | |
| Completed |
NCT05746780 -
Bilateral Elective Neck Dissection in Salvage Total Laryngectomy
|
||
| Recruiting |
NCT05793151 -
Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy
|
N/A | |
| Completed |
NCT01700647 -
Breath Testing in Early and Late Larynx Cancer
|
N/A | |
| Completed |
NCT00169247 -
Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation
|
Phase 2 | |
| Completed |
NCT00600223 -
Functional Voice and Speech Outcomes Following Surgical Voice Restorations: A Comparison of Pharyngeal Construction Approaches
|
N/A | |
| Recruiting |
NCT03759431 -
Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02586207 -
Pembrolizumab in Combination With CRT for LA-SCCHN
|
Phase 1 | |
| Recruiting |
NCT04057209 -
VoiceS: Voice Quality After Transoral CO2-Laser Surgery Versus Single Vocal Cord Irradiation for Larynx Cancer
|
N/A | |
| Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
| Recruiting |
NCT06086119 -
Quality of Life and Voice Perception in Patients Laryngoctomized Phonatory Wearers
|
||
| Suspended |
NCT04368702 -
CONFIRM: Magnetic Resonance Guided Radiation Therapy
|
N/A | |
| Completed |
NCT05217147 -
An Investigation of Biomarker Candidate Molecules in Laryngeal Carcinoma
|
||
| Active, not recruiting |
NCT03082534 -
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT00158652 -
Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC
|
Phase 3 | |
| Terminated |
NCT03479463 -
Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/Pharyngectomy
|
||
| Completed |
NCT03096808 -
Adaptive Radiotherapy for Head and Neck Cancer
|
Phase 2 | |
| Completed |
NCT00359645 -
Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population
|
Phase 3 |